Cerus Stock Forum

Despite recent uplift, the business needs to justify a higher price. Market focus is on revenue growth due to unprofitability. Fast revenue growth doesn't guarantee profits, and if cash is low, capital may need to be raised. Investors should note the 3 warning signs with Cerus.

Cantor Fitzgerald sees AVITA's superior growth and high gross margins as reasons for a premium. The firm also sees potential in Pacific Biosciences and AxoGen, and expects positive share price appreciation for Exagen and NeuroPace. A significant catalyst for Nyxoah's stock is anticipated with upcoming DREAM study data.

Despite notable revenue growth, Cerus' continual drop in share price indicates potential balance sheet issues. This may raise concerns about capital acquisition need. However, contrarian investors may eye the stock hoping for a turnaround.